Table 2.
Patient Demographics
| ID | Age, y | Ethnicity | BMI, kg/m2 | Nicotine Usage | HbAc1, mmol/mol | HTN | Serum Albumin, g/L | Indication for Surgery | Type of Cancer | Cancer Stage |
|---|---|---|---|---|---|---|---|---|---|---|
| 001 | 47 | Pakeha | 22.2 | No | NA | No | 38 | Cancer | Invasive breast carcinoma, ER/PR+, HER2− | IV |
| 002 | 68 | Māori | 24.6 | No | 38 | No | 34 | Cancer | Ductal carcinoma in situ | 0 |
| 003 | 83 | Pakeha | 28.0 | Yes | 33 | No | 36 | Cancer | Micropapillary breast cancer | III |
| 004 | 76 | Pakeha | 26.6 | Former tobacco user | 38 | Yes | NA | PPX | NA | NA |
| 005 | 64 | Asian | 27.0 | No | 49 | Yes | 38 | Cancer | Invasive breast carcinoma | II |
| 006 | 33 | Māori | 25.0 | Yes | NA | No | NA | Tumor | Benign phyllodes tumor | NA |
| 007 | 62 | Pakeha | 30.0 | Yes | NA | No | NA | Cancer | Lobular cancer | I |
| 008 | 58 | Māori | 32.0 | No | NA | No | NA | Cancer | Invasive duct carcinoma | I |
| 009 | 81 | Pakeha | 28.0 | No | 44 | Yes | 34 | Cancer | Invasive lobular cancer | I |
| 010 | 47 | Pakeha | 33.0 | No | 35 | No | 35 | Cancer | Invasive duct carcinoma | I |
| Mean ± SD | 61.9 ± 16.1 | — | 27.6 ± 3.3 | — | 39.5 ± 5.9 | — | 35.83 ± 1.8 | — | — | — |
| Median (IQR) | 63.0 (47.0–77.0) | — | 27.5 (24.9–30.5) | — | 38.0 (34.5–45.2) | — | 35.5 (34.0–38.0) | — | — | — |
BMI, body mass index; ER/PR+, estrogen and progesterone receptor positive; HbA1c, glycated hemoglobin; HER2-, human epidermal growth factor receptor 2 negative; HTN, hypertension; NA, not available; PPX, prophylactic.